首页> 中国专利> 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用

一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明公开一种肝癌细胞的抑制剂。所述的一种肝癌细胞的抑制剂包括PPARγ激动剂与AKT抑制剂曲西立滨，所述的PPARγ激动剂为罗格列酮或15d-PGJ

著录项

公开/公告号CN102940884B

专利类型发明专利
公开/公告日2013-11-06

原文格式PDF
申请/专利权人上海市肿瘤研究所;
展开▼

申请/专利号CN201210464985.4
发明设计人刘永忠;刘兰兰;杨兆娟;
展开▼

申请日2012-11-19
分类号
代理机构上海申汇专利代理有限公司;
代理人吴宝根
地址 200032 上海市徐汇区斜土路2200弄25号
入库时间 2022-08-23 09:16:50

法律信息

法律状态公告日

法律状态信息

法律状态
2013-11-06

授权

授权
2013-04-03

实质审查的生效 IPC(主分类):A61K 45/06 申请日:20121119

实质审查的生效
2013-02-27

公开

公开

相似文献

专利
中文文献
外文文献

1. 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用 [P] . 中国专利： CN102940884B . 2013.11.06
2. 一种肝癌细胞生长抑制剂及其在肝癌预后判断中的应用 [P] . 中国专利： CN108245526A . 2018-07-06
3. STILBENOID COMPOUNDS AS SILICA CELL CARCINOMA AND HEPATOMA INHIBITORS AND THEIR APPLICATION [P] . 俄罗斯专利： RU2014111983A . 2015-10-10

机译：甲硅烷基化合物作为二氧化硅细胞癌和肝癌抑制剂及其应用
4. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066
5. use of a compound selected from the group consisting of a proteasome inhibitor, an autophagy inhibitor, a lysosomal inhibitor, an golgi er protein transport inhibitor, an hsp90 chaperonin inhibitor, a heat shock response activator, a and a histone deacetylase inhibitor, use of 11-cis-retinal or 9-cis-retinal and a compound selected from the group consisting of a proteasome inhibitor, an autophagy inhibitor, a lissosomal inhibitor, a er to golgi protein, a hsp90 chaperonin inhibitor, a heat shock response activator, a glycosidase inhibitor, and a histone deacetylase inhibitor, a method for increasing the amount of a biochemically functional conformation of a protein in a cell, composition pharmaceutical for the treatment of an ocular pcd, pharmaceutical composition for the treatment of retinitis pigmentosa, kit for the treatment of an ocular pcd, kit for the treatment retinitis pigmentosa, method for identifying a compound useful for the treatment of an individual having an ocular pcd, [P] . BRPI0615962A2 . 2011-05-31

机译：使用选自以下的化合物：蛋白酶体抑制剂，自噬抑制剂，溶酶体抑制剂，高尔基体蛋白转运抑制剂，hsp90伴侣蛋白抑制剂，热休克反应激活剂，α和组蛋白脱乙酰酶抑制剂，使用11 -顺式-视黄醛或9-顺式-视黄醛以及选自蛋白酶体抑制剂，自噬抑制剂，核糖体抑制剂，高尔基体蛋白er，hsp90伴侣蛋白抑制剂，热休克反应激活剂，糖苷酶的化合物抑制剂和组蛋白脱乙酰基酶抑制剂，一种增加细胞中蛋白质的生化功能构象量的方法，用于治疗眼pcd的组合物药物，用于治疗色素性视网膜炎的药物组合物，用于治疗视网膜色素变性的试剂盒眼用pcd，用于治疗色素性视网膜炎的试剂盒，用于鉴定可用于治疗具有眼用pcd的个体的化合物的方法，